LL-37 vs VIP
Both LL-37 and VIP are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
LL-37
Evidence BCathelicidin LL-37
The only human cathelicidin antimicrobial peptide. Active against bacteria, viruses, and biofilms. Investigated topically for infected wounds and mucosal infections.
View full LL-37 profile →VIP
Evidence BVasoactive Intestinal Peptide
A 28-amino-acid neuropeptide with broad immunomodulatory effects. Used clinically (intranasal) by some practitioners for chronic inflammatory response syndrome (CIRS).
View full VIP profile →Side-by-Side
| Attribute | LL-37 | VIP |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved — endogenous antimicrobial peptide; clinical trials for infected wounds | Not FDA-approved — investigational; ongoing trials for sarcoidosis |
| Typical Dose | Trial range: topical or intralesional | 50 mcg intranasal, 4 times daily (CIRS protocols) |
| Clinics Indexed | 19 | 24 |
| Categories | immune, anti-inflammatory | anti-inflammatory, neuroprotection |
Key reported benefits — LL-37
- ✓Broad antimicrobial activity
- ✓Wound healing
- ✓Anti-biofilm
Key reported benefits — VIP
- ✓Anti-inflammation
- ✓Pulmonary effects
- ✓Neuroprotection
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.